Embolic protection device use and its association with procedural safety and long-term outcomes following saphenous vein graft intervention: An analysis from the British Columbia Cardiac registry

Catheterization and Cardiovascular Interventions

Volumn 88, Issue 1, 2016, Pages 73-83

  Iqbal, M Bilal ^a,b   Nadra, Imad J ^a,b   Ding, Lillian ^c   Fung, Anthony ^d   Aymong, Eve ^e   Chan, Albert W ^f   Hodge, Steven ^g   Della Siega, Anthony ^a,b   Robinson, Simon D ^a,b  

^a Victoria Heart Institute Foundation   (Canada)

^b ROYAL JUBILEE HOSPITAL   (Canada)

^c PROVINCIAL HEALTH SERVICES AUTHORITY   (Canada)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

^e ST PAUL S HOSPITAL   (Canada)

^f ROYAL COLUMBIAN HOSPITAL   (Canada)

^g KELOWNA GENERAL HOSPITAL   (Canada)

Author keywords

embolic protection device; mortality; post procedural flow; saphenous vein graft; target vessel revascularization

Indexed keywords

ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR RESPONSE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DEVICE SAFETY; EMBOLIC PROTECTION DEVICE; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; RETROSPECTIVE STUDY; SAPHENOUS VEIN GRAFT; SCORING SYSTEM; TARGET VESSEL REVASCULARIZATION;

EID: 84978924408     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.26237     Document Type: Article

References (31)

1. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994;89:2514–2518.
2. Hong MK, Mehran R, Dangas G, et al. Creatine kinase-mb enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. Circulation 1999;100:2400–2405.
3. Baim DS, Wahr D, George B, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002;105:1285–1290.
4. Levine GN, Bates ER, Blankenship JC, et al. 2011 accf/aha/scai guideline for percutaneous coronary intervention: Executive summary: A report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Catheter Cardiovasc Intervent 2012;79:453–495.
5. Abdel-Karim AR, Papayannis AC, Mahmood A, et al. Role of embolic protection devices in ostial saphenous vein graft lesions. Catheter Cardiovasc Intervent 2012;80:1120–1126.
6. Mehilli J, Pache J, Abdel-Wahab M, et al. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (isar-cabg): A randomised controlled superiority trial. Lancet 2011;378:1071–1078.
7. Senter SR, Nathan S, Gupta A, Klein LW. Clinical and economic outcomes of embolic complications and strategies for distal embolic protection during percutaneous coronary intervention in saphenous vein grafts. J Invasive Cardiol 2006;18:49–53.
8. Lee MS, Park SJ, Kandzari DE, et al. Saphenous vein graft intervention. JACC Cardiovasc Intervent 2011;4:831–843.
9. Brennan JM, Al-Hejily W, Dai D, et al. Three-year outcomes associated with embolic protection in saphenous vein graft intervention: Results in 49 325 senior patients in the medicare-linked national cardiovascular data registry cathpci registry. Circ Cardiovasc Interv 2015;8:e001403.
10. Mahmud E, Shaw KD, Penny WF. Patients at low risk for periprocedural myocardial infarction can be identified by assessment immediately following percutaneous coronary intervention. J Invasive Cardiol 2003;15:343–347.
11. Nallamothu BK, Chetcuti S, Mukherjee D, et al. Prognostic implication of troponin i elevation after percutaneous coronary intervention. Am J Cardiol 2003;91:1272–1274.
12. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: Wiley; 2000.
13. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: A monte carlo study. Stat Med 2007;26:734–753.
14. Valgimigli M, Saia F, Guastaroba P, et al. Transradial versus transfemoral intervention for acute myocardial infarction: A propensity score-adjusted and -matched analysis from the real (registro regionale angioplastiche dell'emilia-romagna) multicenter registry. JACC Cardiovasc Interv 2012;5:23–35.
15. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: A comparative study. Stat Med 2004;23:2937–2960.
16. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology (Cambridge, Mass.) 2000;11:550–560.
17. Stone GW, Rogers C, Hermiller J, et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation 2003;108:548–553.
18. Carrozza JP Jr, Mumma M, Breall JA, et al. Randomized evaluation of the triactiv balloon-protection flush and extraction system for the treatment of saphenous vein graft disease. J Am Coll Cardiol 2005;46:1677–1683.
19. Kereiakes DJ, Turco MA, Breall J, et al. A novel filter-based distal embolic protection device for percutaneous intervention of saphenous vein graft lesions: Results of the amethyst randomized controlled trial. JACC Cardiovasc Interv 2008;1:248–257.
20. Mauri L, Cox D, Hermiller J, et al. The proximal trial: Proximal protection during saphenous vein graft intervention using the proxis embolic protection system: A randomized, prospective, multicenter clinical trial. J Am Coll Cardiol 2007;50:1442–1449.
21. Dixon SR, Mann JT, Lauer MA, et al. A randomized, controlled trial of saphenous vein graft intervention with a filter-based distal embolic protection device: Trap trial. J Interv Cardiol 2005;18:233–241.
22. Mehta SK, Frutkin AD, Milford-Beland S, et al. Utilization of distal embolic protection in saphenous vein graft interventions (an analysis of 19,546 patients in the american college of cardiology-national cardiovascular data registry). Am J Cardiol 2007;100:1114–1118.
23. Leborgne L, Cheneau E, Pichard A, et al. Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft. Am Heart J 2003;146:501–506.
24. Hong YJ, Pichard AD, Mintz GS, et al. Outcome of undersized drug-eluting stents for percutaneous coronary intervention of saphenous vein graft lesions. Am J Cardiol 2010;105:179–185.
25. Maia F, Costa JR Jr, Abizaid A, et al. Preliminary results of the inspire trial with the novel mguard stent system containing a protection net to prevent distal embolization. Catheter Cardiovasc Interv 2010;76:86–92.
26. Niccoli G, Belloni F, Cosentino N, et al. Case-control registry of excimer laser coronary angioplasty versus distal protection devices in patients with acute coronary syndromes due to saphenous vein graft disease. Am J Cardiol 2013;112:1586–1591.
27. Golwala H, Hawkins BM, Stavrakis S, Abu-Fadel MS. Embolic protection device use and outcomes in patients receiving saphenous vein graft interventions–a single-center experience. J Invasive Cardiol 2012;24:1–3.
28. Post PN, Kuijpers M, Ebels T, Zijlstra F. The relation between volume and outcome of coronary interventions: A systematic review and meta-analysis. Eur Heart J 2010;31:1985–1992.
29. McGrath PD, Wennberg DE, Dickens JD Jr, et al. Relation between operator and hospital volume and outcomes following percutaneous coronary interventions in the era of the coronary stent. J Am Med Assoc 2000;284:3139–3144.
30. Iqbal MB, Arujuna A, Ilsley C, et al. Radial versus femoral access is associated with reduced complications and mortality in patients with non-st-segment-elevation myocardial infarction: An observational cohort study of 10,095 patients. Circ Cardiovasc Interv 2014;7:456–464.
31. Fischell TA, Subraya RG, Ashraf K, Perry B, Haller S. “Pharmacologic” distal protection using prophylactic, intragraft nicardipine to prevent no-reflow and non-q-wave myocardial infarction during elective saphenous vein graft intervention. J Invasive Cardiol 2007;19:58–62.